Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 102, Issue 2, Pages 213-218Publisher
WILEY
DOI: 10.1002/cpt.598
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R24GM115264, R24GM61374, RO1 GM008076-05]
- EU HB020 UPGx grant [668353]
- Robert Bosch Foundation, Stuttgart, Germany
- National Institutes of Health eMERGE Network Phase III [U01HG8666]
Ask authors/readers for more resources
The 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e., ondansetron and tropisetron), thereby affecting drug efficacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www.pharmgkb.org and cpicpgx.org).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available